Stroke Prevention by ORal Thrombin Inhibitor in atrial Fibrillation III "SPORTIF III"

Completed

Phase N/A Results

Summary of Purpose

To determine the safety and efficacy of an oral direct thrombin inhibitor Exanta (ximelagatran) with those of dose adjusted warfarin (coumadin) in preventing stroke and systemic embolic events in patients with atrial fibrillation.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 4 September 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • AstraZeneca

Trial Design

Randomized, open-label, parallel-group study with blinded event assessment.

Contacts

Not available